Last reviewed · How we verify
Drug：JS001, Intravenous infusion
Drug：JS001, Intravenous infusion is a Biologic drug developed by Shanghai Junshi Bioscience Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Drug：JS001, Intravenous infusion |
|---|---|
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug：JS001, Intravenous infusion CI brief — competitive landscape report
- Drug：JS001, Intravenous infusion updates RSS · CI watch RSS
- Shanghai Junshi Bioscience Co., Ltd. portfolio CI
Frequently asked questions about Drug：JS001, Intravenous infusion
What is Drug：JS001, Intravenous infusion?
Drug：JS001, Intravenous infusion is a Biologic drug developed by Shanghai Junshi Bioscience Co., Ltd..
Who makes Drug：JS001, Intravenous infusion?
Drug：JS001, Intravenous infusion is developed by Shanghai Junshi Bioscience Co., Ltd. (see full Shanghai Junshi Bioscience Co., Ltd. pipeline at /company/shanghai-junshi-bioscience-co-ltd).
What development phase is Drug：JS001, Intravenous infusion in?
Drug：JS001, Intravenous infusion is in Phase 1.